Farnesoid X receptor modulators (2011-2014): A patent review

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 8, 2015, Pages 885-896

  Sepe, Valentina ^a   Distrutti, Eleonora ^b   Fiorucci, Stefano ^c   Zampella, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Farnesoid X receptor modulators; Non steroidal ligands; Patents on 2011 2014; Steroidal ligands

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BENZIMIDAZOLE DERIVATIVE; BILE ACID; BILE ACID SEQUESTRANT; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FARNESOID X RECEPTOR ANTAGONIST; FARNESOID X RECEPTOR MODULATOR; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

DRUG EFFICACY; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INBORN ERROR OF METABOLISM; INTRAHEPATIC CHOLESTASIS; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; ANIMAL; CHOLESTASIS; DRUG DESIGN; DRUG EFFECTS; LIVER DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS; DRUG DESIGN; HUMANS; LIVER DISEASES; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84937207119     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1045413     Document Type: Review

References (66)

1. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687-93
2. Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995;9:72-85
3. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-53
4. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8
5. Makishima M, Okamoto AY, Repa JJ. et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5
6. Swanson HI, Wada T, Xie W, et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos 2013;41:1-11
7. Fiorucci S, Cipriani S, Baldelli F, et al. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2010;49:171-85
8. Fiorucci S, Mencarelli A, Palladino G, et al. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30:570-80
9. Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007;13:298-309
10. Fiorucci S, Cipriani S, Mencarelli A, et al. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 2010;10:579-95
11. Tsuei J, Chau T, Mills D, et al. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med 2014;239:1489-504
12. Otte K, Kranz H, Kober I, et al. Identification of farnesoid X receptor b as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 2003;23:864-72
13. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 1997;9:222-32
14. Rizzo G, Renga B, Antonelli E, et al. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 2005;68:551-8
15. Sepe V, Renga B, Festa C, et al. Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cellsurface G-protein coupled bile acid receptor 1 (GP-BAR1). J Med Chem 2014;57:7687-701
16. Gonzalez FJ, Jiang C, Bisson WH, et al. Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity. J Hepatol 2015;doi: 10. 1016/j. jhep. 2015. 02. 043. [Epub ahead of print]
17. Mi LZ, Devarakonda S, Harp JM, et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 2003;11:1093-100
18. Wang L, Lee YK, Bundman D, et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002;2:721-31
19. Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol 2005;400:511-30
20. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004;126:322-42
21. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25
22. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 2015;26:22-9
23. Davern TJ, Scharschmidt BF. Biochemical liver test. In: Gastrointestinal and liver disease. Sleisenger and Fordtran's Edition; 2002. p. 1227-37
24. Pellicciari R, Gioiello A, Costantino G. Potential therapeutic applications of farnesoid x receptor (FXR) modulators. Expert Opin Ther Pat 2006;16:333-41
25. Crawley ML. Farnesoid X receptor modulators: A patent review. Expert Opin Ther Pat 2010;20:1047-57
26. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21:159-65
27. Pellicciari R, Fiorucci S, Camaioni E, et al. 6-alpha-etyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72
28. Intercert Pharmaceuticals Inc. Preparation, uses and solid forms of obeticholic acid. WO2013192097A1; 2013
29. Fiorucci S, Cipriani S, Mencarelli A, et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev. Med. Chem 2011;11:753-62
30. Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51:771-84
31. Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009;175:2392-405
32. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59:2286-98
33. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-82
34. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65
35. Fiorucci S, Distrutti E, Ricci P, et al. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets 2014;18:1449-59
36. Mason A, Luketic V, Lindor K, et al. Farnesoid-X receptor agonists: A new class of drugs for the treatment of PBC An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010;52:S1-2
37. D'Amore C, Di Leva FS, Sepe V, et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem 2014;57:937-54
38. Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acidinduced itch and analgesia. J Clin Invest 2013;123:1513-30
39. Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014;60:399-407
40. Amarin Pharmaceuticals Ireland Limited. Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis. US 20140187633; 2014
41. Amarin Pharmaceuticals Ireland Limited. Composition comprising EPA and obeticholic acid and methods of use thereof. US 20140186438; 2014
42. TesPharmaS. r. l. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid X receptor modulators. WO2014184271; 2014
43. S. Fatty acid conjugates of statin and FXR agonists; composition and method of uses. WO2013166176 A1; 2013
44. Gege C, Kinzel O, Steeneck C, et al. Knocking on FXR's Door: the "hammerhead"-structure series of FXR agonists-amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 2014;14:2143-58
45. Carotti A, Marinozzi M, Custodi C, et al. Beyond bile acids: targeting farnesoid x receptor (FXR) with naturaland synthetic ligands. Curr Top Med Chem 2014;14:2129-42
46. Phenex Pharmaceuticals AG. Novel FXR. NR1H4 binding and activity modulating compounds. WO2011020615A1; 2011
47. Hambruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic lowdensity lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 2012;343:556-67
48. Safety pilot study of farnesoid X receptor (FXR) agonist in non-alcoholic fatty liver disease (NAFLD) patients U. S. National Institutes of Health, Responsible Party: Phenex Pharmaceuticals AG, Health Authority: Austria: Austrian Medicines and Medical Devices Agency. Available from: https://clinicaltrials. gov/ct2/show/ NCT01999101
49. Phenex Pharmaceuticals AG. Novel FXR. NR1H4) binding and activity modulating compound. WO2013007387A1; 2013
50. Phenex Pharmaceuticals AG. Heterocyclic FXR binding compounds. WO2008025540; 2008
51. Phenex Pharmaceuticals AG. Farnesoid X receptor agonists for cancer treatment and prevention. WO2013037482A1; 2013
52. Deuschle U, Schüler J, Schulz A, et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS ONE 2012;7:e43044
53. IRM LLC. Composition and methods for modulating FXR. WO12087519A1; 2012
54. IRM LLC. Compositions and methods for modulating farnesoid X receptors. WO2012087520A1; 2012
55. IRM LLC. Compositions and methods for modulating farnesoid X receptors. WO2012087521 A1; 2012
56. Richter HGF, Benson GM, Blum D, et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 2011;21:191-4
57. Richter HGF, Benson GM, Bleicher KH, et al. Optimization of a novel class of benzimidazole-based farnesoid x receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorg Med Chem Lett 2011;21:1134-40
58. Hoffmann-La Roche Inc. New benzimidazole derivatives. WO2010043513; 2010
59. Hoffmann-La Roche Inc. New benzimidazole derivatives. WO 20110077273; 2011
60. Hoffmann-La Roche Inc. Cyclopentyland cycloheptylpyrazoles as FXR modulators. WO2011117163A1; 2011
61. Cadila Pharmaceuticals LTD. Vaccine adjuvants. WO2010035119A2; 2010
62. The University of Chicago. FXR inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction. WO2012106581A1; 2012
63. Reschly EJ, Ai N, Ekins S, et al. Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res 2008;49:1577-87
64. Di Leva FS, Festa C, D'Amore C, et al. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J Med Chem 2013;56:4701-17
65. The United State of America, Department of Health and Human Service and The Penn State Research Foundation. Inhibitors of the farnesoid x receptor and uses in medicine. WO2015017813A2; 2015
66. Festa C, Renga B, D'Amore C, et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor1 (GP-BAR1) ligands. J Med Chem 2014;57:8477-95